银杏内酯注射液联合多巴丝肼和普拉克索对帕金森病患者的临床疗效

Clinical effects of Ginkgolides Injection combined with dopazide and pramipexo lein on patients with Parkinson's disease

目的 探讨银杏内酯注射液联合多巴丝肼和普拉克索对帕金森病患者的临床疗效.方法 80例患者随机分为观察组和对照组,每组40例,对照组给予多巴丝肼和普拉克索,观察组在对照组基础上加用银杏内酯注射液,疗程3个月.检测临床疗效、血清软骨糖蛋白39(YKL-40)、肝X受体β(LXRβ)、人帕金森蛋白7(PARK7)、统一帕金森氏病评分量表(UPDRS)、Hoehn-Yahr分期、不良反应发生率变化.结果 观察组总有效率高于对照组(P<0.05).治疗后,观察组YKL-40、PARK7、UPDRS评分、Hoehn-Yahr分期低于对照组(P<0.05),LXRβ水平更高(P<0.05).2组不良反应发生率比较,差异无统计学意义(P>0.05).结论 银杏内酯注射液联合多巴丝肼和普拉克索可有效调节帕金森病患者血清YKL-40、LXRβ、PARK7水平,促进疾病恢复,值得临床应用和推广.

AIM To explore the clinical effects of Ginkgolides Injection combined with dopazide and pramipexolein on patients with Parkinson's disease.METHODS Eighty patients were randomly assigned into con trol group(40 cases)for 3 month administration of dopazide and pramipexolein,and observation group(40 cases)for 3 month administration of Ginkgolides Injection combined with dopazide and pramipexolein.The changes in clin ical efficacy,serum cartilage glycoprotein 39(YKL 40),liver X receptorβ(LXRβ),human Parkinson protein 7(PARK7),unified Parkinson's disease rating scale(UPDRS),Hoehn Yahr stage and incidence of adverse re actions were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05).After the treatment,the observation group displayed lower YKL 40,PARK7,UPDRS score and Hoehn Yahr stage than the control group(P<0.05),along with higher LXRβlevel(P<0.05).No significant difference in incidence of adverse reactions was found between the two groups(P>0.05).CONCLUSION For the patients with Parkinson's disease,Ginkgolides Injection combined with dopazide and pramipexolein can effec tively regulate serum YKL 40,LXRβand PARK7 levels,and promote disease recovery,which is worth of clinical application and popularization.